.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Cantor Fitzgerald
McKinsey
Julphar
Healthtrust
Chubb
Chinese Patent Office
Fuji
Federal Trade Commission
Merck

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,789,379 protect, and when does it expire?


Patent ► Subscribe protects GATTEX KIT and is included in one NDA.

This patent has fifty-two patent family members in seventeen countries.

Summary for Patent: ► Subscribe

Title: Glucagon-like peptide-2 analogs
Abstract:Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
Inventor(s): Drucker; Daniel J. (Toronto, CA), Crivici; Anna E. (Toronto, CA), Sumner-Smith; Martin (Bolton, CA)
Assignee: Allelix Biopharmaceutical Inc. (Mississauga, CA) 1149336 Ontario Inc. (Toronto, CA)
Application Number:08/669,791
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► SubscribeYY TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,888,317Glucagon-like peptide-2 and its therapeutic use► Subscribe
5,834,428 Glucagon-like peptide-2 and its therapeutic use► Subscribe
6,184,201 Intestinotrophic glucagon-like peptide-2 analogs► Subscribe
7,781,401Glucagon-like peptide-2 analogs► Subscribe
7,049,284Glucagon-like peptide-2 and its therapeutic use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2334864► Subscribe
European Patent Office2275438► Subscribe
European Patent Office2218734► Subscribe
European Patent Office2009024► Subscribe
European Patent Office1988100► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Teva
Daiichi Sankyo
Moodys
Dow
Fish and Richardson
Chubb
Fuji
Queensland Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot